Kearney study sets out 12 recommendations to revitalise medical policy in France in a post-COVID-19 era
Tasked by Leem with conducting a global study on the impacts of COVID-19 on the health sector, the consulting firm Kearney has released a study that sets out its 12 recommendations to strengthen the French health industry in a post-COVID-19 world.
The report praises the medical industry for its ability to adapt to the challenges brought about by the pandemic. In particular, the study notes the industry’s efforts to accelerate research, increase production capacities in order to ensure continued access to treatments, and mobilise 100,000 workers in the health sector to respond to population needs during the crisis.
Nonetheless, the study also finds that the pandemic has brought some of the French health system’s weaknesses to the fore. These include a dependence on international chains of production based outside of Europe, and a loss of competitiveness in drug production compared to other European countries.
Kearney’s report sets out its recommendations to improve the competitiveness and efficiency of the French pharmaceutical industry. These include measures that aim to:
- make France a European leader in terms of innovation and industrialisation
- establish a sharing strategy to allow the access and analysis of health data
- accelerate the digitalisation of the health ecosystem
- develop European cooperation
- learn from the lessons presented by the crisis.
Read the full Leem article for more information.